2017
DOI: 10.1016/j.ijpharm.2017.02.031
|View full text |Cite
|
Sign up to set email alerts
|

Dissecting the role of the elongation factor 1A isoforms in hepatocellular carcinoma cells by liposome-mediated delivery of siRNAs

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
17
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 18 publications
(18 citation statements)
references
References 39 publications
1
17
0
Order By: Relevance
“…Indeed, a detailed knowledge of nanostructure is mandatory to properly design and optimize drug delivery system based on polymers such as IPN. This is particularly true in the case of the release of active agents that need to be embedded inside liposomes or on their surface in order to protect them till they reach the site action as it happens in the case of the fragile Nucleic Acid Based Drugs [31][32][33][34][35][36][37].…”
Section: Discussionmentioning
confidence: 99%
“…Indeed, a detailed knowledge of nanostructure is mandatory to properly design and optimize drug delivery system based on polymers such as IPN. This is particularly true in the case of the release of active agents that need to be embedded inside liposomes or on their surface in order to protect them till they reach the site action as it happens in the case of the fragile Nucleic Acid Based Drugs [31][32][33][34][35][36][37].…”
Section: Discussionmentioning
confidence: 99%
“…Among these processes, the eukaryotic elongation factor 1 (eEF1) complex plays an indispensable function in eukaryotic protein peptide chain elongation in all eukaryotic cells [13] , [14] . eEF1A1, eukaryotic elongation factor 1 alpha 1 (eEF1A2) and eEF1Bαβγ subcomplex [15] . Human eEF1A1 is a core subunit of the eEF1 complex that shows ability for GTP binding as well as amino acid-tRNA delivery [16] .…”
Section: Introductionmentioning
confidence: 99%
“…Blanch et al [24] suggested that eEF1A1 was a negative regulator of p53 and p73, since silencing of eEF1A1 partially rescued the anti-apoptosis and chemoresistance observed in response to p53 or p73 knockdown. Farra et al [15] reported that eEF1A1 depletion in HCC downregulated the transcription factor E2F1 to induce the G1/G0 cell cycle block. However, the clinical significance of eEF1A1 in tumor development and progression has not yet been reported.…”
Section: Introductionmentioning
confidence: 99%
“…LMNA (A-type lamin) has been shown to control transcription of BRCA1 [47]. EEF1A1 (translation elongation factor 1-alpha 1) affects gene expression through regulating mRNA stability [48], and could also regulate BRCA1 through E2F1 [50, 51]. Therefore, the ultimate BRCA1 protein level is regulated by CTSO at both transcription as well as protein levels.…”
Section: Discussionmentioning
confidence: 99%